ArticleJournal of virology2025
ARGLU1 is a negative regulator of the adenoviral replicative cycle.
Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
We have previously reported that human adenovirus E1A interacts with ARGLU1, a small disordered cellular protein. The consequences of this interaction for virus replication were unclear. E1A is the first protein produced during adenovirus infection. Via protein-protein interactions, E1A modifies the cellular environment to create optimal conditions for viral replication. To better understand the molecular mechanisms driving viral infection, we further investigated the functional consequences of the interaction between ARGLU1 and E1A. ARGLU1 interacts with E1A directly as determined by a GST-pulldown assay with recombinant proteins. Importantly, ARGLU1 was found to act as a transcriptional repressor when it was localized to viral promoters. Repression was driven by enhanced promoter-proximal RNA polymerase II pausing. Significantly, ARGLU1-induced repression of viral promoters is likely an unintended consequence of ARGLU1 binding to E1A, as a mutant of E1A (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.